{"nctId":"NCT00594958","briefTitle":"Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51","startDateStruct":{"date":"2006-09"},"conditions":["Japanese Encephalitis"],"count":639,"armGroups":[{"label":"IC51 Group A","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51"]},{"label":"IC51 Group B","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51"]},{"label":"IC51 Group C","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51"]}],"interventions":[{"name":"IC51","otherNames":["Japanese Encephalitis purified inactivated vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Male and female subjects aged at least 18 years with written informed consent and either no childbearing potential or negative pregnancy test\n\nMain Exclusion Criteria:\n\n* History of immunodeficiency or immunosuppressive therapy, known HIV, drug addiction including alcohol dependence","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"GMT for Anti-JEV Neutralizing Antibody","description":"Equivalence between batches with regards to GMT (Geometric Mean Titer) was postulated if all three pair-wise 95 % Confidence Intervals for GMT ratios were between 0.5 and 2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160.71","spread":null},{"groupId":"OG001","value":"272.24","spread":null},{"groupId":"OG002","value":"127.56","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety","description":"Safety laboratory parameters, rate of SAEs and medically attended AEs, systemic and local tolerability","classes":[]},{"type":"SECONDARY","title":"SCR for Anti-JEC Neutralizing Antibody Titer","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":212},"commonTop":["Headache","Nasopharyngitis","Influenza Like Ilness","Fatigue","Myalgia"]}}}